We develop drug-product formulations for poorly-soluble small molecules, carrying your program from discovery through GLP-tox, under one roof, led by scientists who've done it before.
Scientists with deep formulation and nanomedicine experience.
We've carried programs from early discovery into clinical trials.
Most studies are run by our own experienced scientists, under one roof, from discovery through GLP-tox.
Purpose-built for high-potency, cytotoxic and poorly-soluble small molecules, including high-OEB compounds most CDMOs cannot handle.
Increasingly potent small molecules are limited not by their mechanism, but by their delivery. They degrade in the bloodstream before reaching the target, or distribute everywhere and poison healthy tissue. The science is sound. The delivery isn't.
More than 60% of drug candidates in development have extremely low aqueous solubility, making them hard to formulate, dose and absorb, and stalling otherwise-promising molecules before they reach the clinic.
Molecules are cleared or degraded before reaching the target, demanding higher, more frequent doses and producing inconsistent exposure.
Systemic distribution exposes healthy tissue, narrowing the therapeutic window and causing dose-limiting side effects.
Our platform encapsulates small molecules with extremely low solubility in polymeric or lipid systems, protecting the drug payload and extending its circulation so the drug can accumulate at the site of action.
Shield potent molecules in circulation so they stay intact on the way to the target.
Direct the dose to the disease site, raising local exposure where it matters most.
Reduce systemic distribution and the dose-limiting toxicity that comes with it.
Our edge isn't a black box: it's a senior team with deep nanomedicine experience that has carried programs from early discovery, through preclinical development, and into clinical trials. We know what it takes to make a formulation work in the real world.
Years of hands-on experience engineering polymeric and lipid nanocarriers for poorly-deliverable small molecules.
We've taken programs the full distance, from first feasibility through preclinical studies and into the clinic.
An experienced team that knows FDA guidance and CMC regulatory requirements, so formulation, analytical and manufacturing work is documented to IND expectations from the first experiment.
A clear, staged path that turns a delivery problem into a characterized, reproducible formulation, with go/no-go decisions built in.
We assess your molecule and the delivery bottleneck, then scope a concrete feasibility proposal.
Design-of-Experiments and automated multi-well screening, with early in-vitro and PK studies, guide candidate selection.
Formulation and release tuning to hit your stability, exposure and tolerability targets.
A representative, characterized drug-product lot, then scale-up and IND-enabling studies with partners.
One partner from discovery to GLP-tox. Most studies run in-house, with qualified CDMO and specialist partners where it adds value. We carry your molecule along the full preclinical path: feasibility, DOE-driven optimization, analytical characterization, and IND-enabling studies.
Design of Experiments and Quality-by-Design (QbD) approaches map the formulation space efficiently, finding robust, reproducible optima in far fewer experiments.
DP0 formulations translated into larger, reproducible, GMP-ready batches through integrated CDMO capability.
Characterized drug-product lots prepared to support GLP toxicology and IND-enabling safety packages.
GMP-grade manufacturing of clinical trial material, including high-potency and cytotoxic (high-OEB) compounds, supporting your program from first-in-human studies through later phases.
PK/PD, biodistribution, efficacy and tolerability in relevant animal models, de-risking the path to the clinic.
High-throughput, multi-well screening explores more candidates per cycle than slow, manual iteration.
Particle size, encapsulation efficiency, excipient and drug concentration, osmolarity, stability and in vitro release (IVR), fully characterized against your target product profile.
Vahana Bio formulates and fills high-OEB materials, including cytotoxics, a capability few CDMOs in North America offer. Containment, cleaning validation and aseptic fill capacity are in place, so potent programs move forward instead of waiting for a facility that will take them.
Programs across the full occupational exposure band (OEB) range, including OEB 4 and 5 cytotoxics. Isolator and glove-box containment, with a program-specific cleaning risk assessment completed before work begins.
Up to 1,200 vials per day, extended across multi-day campaigns for larger batches. Each campaign is qualified with media fills before product is run.
Potent small molecules and general cytotoxics, plus synthetic nucleic acid payloads such as oligonucleotides and mRNA, an area of active and growing work.
Scope: synthetic APIs and nucleic acids. Tell us your modality and containment class and we will confirm fit at feasibility.
Vahana Bio sits where advanced drug delivery, disease-targeted delivery systems and outsourced formulation development converge. The platform is indication-agnostic: it applies to any disease where protecting a molecule in circulation and concentrating it at the target improves the outcome. Oncology is one well-documented example of that need, not the limit of it.
Vancouver is a global hub for lipid-nanoparticle design, yet most players focus on macromolecules like nucleic acids. Vahana Bio is differentiated by focusing on small molecules, a far broader universe of therapeutic opportunity.
A senior team that has taken programs from discovery to the clinic, moving from feasibility to a drug-product lot quickly, where others stay slow.
Indication-agnostic expertise purpose-built for the poorly-soluble, hard-to-deliver molecules that the field underserves.
A lean, senior team reaches meaningful milestones on a disciplined budget, and structures deals for near-term value plus downstream upside.
We don't just automate our own lab. Our engineers turn complicated, manual workflows into reliable automation for other labs too, cutting material consumption and cost while lifting throughput.
Automated handling cuts reagent, sample and consumable waste per result.
Run more experiments, faster, with consistent and repeatable results.
Fewer manual hours and less rework drive down the cost per data point.
Experienced engineers study your process and needs, then map where automation delivers the biggest gains.
We design and validate a working proof of concept that de-risks the approach before you commit.
We build and deliver the automated equipment, from custom rigs to fully integrated systems.
Lead with a non-confidential overview. We'll come back with a concrete feasibility proposal, and a path to a Vahana Bio formulation.